NCT00086567 2026-04-08
Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
National Institutes of Health Clinical Center (CC)
Completed
Clinical Trials
425 trialsNCT02122185 2026-03-27
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
Phase 2 Completed
NCT04415944 2026-03-19
HIPEC
Wake Forest University Health Sciences
Phase 2 Completed
NCT04539327 2026-03-18
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
Grupo EspaƱol de InvestigaciĆ³n en CĆ”ncer de Ovario
Completed
NCT04027868 2026-02-17
GREAT
ARCAGY/ GINECO GROUP
Completed
NCT05325866 2026-02-04
FORTITUDE-301
Amgen
Phase 1/2 Completed
NCT06086665 2026-02-04
REFIRM
Asan Medical Center
Completed
NCT03622385 2026-01-23
Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer
Baylor Research Institute
Completed
NCT06173037 2026-01-07
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
RemeGen Co., Ltd.
Phase 2 Completed
NCT05483933 2025-12-23
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
Phase 1 Completed
NCT05613088 2025-10-20
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT05293496 2025-10-14
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
Phase 1 Completed
NCT04209855 2025-08-27
MIRASOL
AbbVie
Phase 3 Completed
NCT05585034 2025-08-07
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAbĀ®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
Phase 1 Completed
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT02159716 2025-06-29
CART-meso in Mesothelin Expressing Cancers
University of Pennsylvania
Phase 1 Completed
NCT01309230 2025-06-08
A Trial of FANGā¢ Vaccine for Participants With Ovarian Cancer
Gradalis, Inc.
Phase 2 Completed
NCT06087289 2025-06-08
KANDOVA
Novakand Pharma AB
Phase 1/2 Completed
NCT00436254 2025-04-06
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
University of Washington
Phase 1 Completed
NCT04925284 2025-04-04
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
Phase 1 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT02480374 2024-10-02
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer
Imunon
Phase 1 Completed
NCT05700669 2024-09-19
Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors
Valerio Therapeutics
Phase 1/2 Completed
NCT04296890 2024-08-07
SORAYA
ImmunoGen, Inc.
Phase 3 Completed
NCT02344095 2024-07-12
POPOPO
Seoul National University Hospital
Phase 1 Completed
NCT06483399 2024-07-03
Research on Nutritional Risk Indexes and Inflammatory Indicators in Postoperative Complications and Prognosis of Epithelial Ovarian Cancer Patients
Tongji Hospital
Completed
NCT02606305 2024-06-14
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRĪ±) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
Phase 1/2 Completed
NCT03093155 2024-05-14
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
Phase 2 Completed
NCT02668913 2024-05-09
LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer
University of Leeds
Phase NA Completed
NCT04676334 2024-05-07
CATCH-R
pharmaand GmbH
Phase 3 Completed
NCT01439490 2024-05-06
FES-PET to Determine ER-expression in Epithelial Ovarian Cancer
University Medical Center Groningen
Phase 2 Completed
NCT02312661 2024-05-06
OVMET
University Medical Center Groningen
Phase 1 Completed
NCT06366997 2024-04-16
Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test
Chongqing University Cancer Hospital
Completed
NCT04148937 2024-04-05
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02728830 2024-02-21
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
Duke University
Phase EARLY_PHASE1 Completed
NCT00408590 2024-01-16
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Mayo Clinic
Phase 1 Completed
NCT02915523 2024-01-10
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT01402271 2023-12-11
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed
NCT02477202 2023-10-16
MirenaĀ® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT00066729 2023-10-04
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT00072410 2023-10-04
Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT00112957 2023-10-04
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Ludwig Institute for Cancer Research
Phase 2 Completed
NCT00803569 2023-10-04
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT00562640 2023-09-15
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01506856 2023-09-15
iPocc
Gynecologic Oncology Trial & Investigation Consortium
Phase 2/3 Completed
NCT01164995 2023-09-07
M10MKO
The Netherlands Cancer Institute
Phase 2 Completed
NCT00993655 2023-08-28
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00471432 2023-08-04
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Canadian Cancer Trials Group
Phase 1 Completed
NCT01891344 2023-06-12
ARIEL2
pharmaand GmbH
Phase 2 Completed
NCT02855944 2023-06-09
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Phase 3 Completed